公开(公告)号：US20240238214A1

公开(公告)日：2024-07-18

申请号：US18580977

申请日：2022-07-20

Applicant: Purdue Research Foundation

Inventor： Yoon Yeo ,  Soonbum Kwon

IPC: A61K9/51 ,  A61K31/337 ,  A61K38/07 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K9/5146 ,  A61K9/5123 ,  A61K9/5169 ,  A61K31/337 ,  A61K38/07 ,  A61K39/3955 ,  A61P35/00

Abstract: Nanoconstructs and compositions comprising a nanoparticle coated with an immunoadjuvant (e.g. ATP) and comprising one or more therapeutic agents (e.g. ICD inducer) encapsulated therein; and methods for treating cancer in a subject using such nanoconstructs and compositions, as well as combination immunotherapies.

公开(公告)号：US20230248689A1

公开(公告)日：2023-08-10

申请号：US18012589

申请日：2021-06-24

Applicant: Purdue Research Foundation ,  THE TRUSTEES OF INDIANA UNIVERSITY ,  Dr. Reddy's Laboratories Limited

Inventor： Yoon Yeo ,  Dhawal Chobisa ,  Timothy W. Corson

IPC: A61K31/343 ,  A61K9/51

CPC classification number: A61K31/343 ,  A61K9/5153

Abstract: The present invention relates to pharmaceutical formulations for long-term ocular delivery of the active agents. The present invention further provides the long-term ocular delivery of griseofulvin with specific in vitro release profile. These formulations are used for the treatment of neovascular eye diseases and age-related macular degeneration (AMD). In particular, the present invention provides microparticles & nanoparticles of griseofulvin for the long-term ocular delivery and methods of preparation of such formulations.

公开(公告)号：US20200060989A1

公开(公告)日：2020-02-27

申请号：US16612038

申请日：2018-05-08

Applicant: Purdue Research Foundation

Inventor： Yoon Yeo ,  Jun Xu

IPC: A61K31/05 ,  A61K9/16 ,  A61P35/00

Abstract: The present invention generally relates to targeted nanoparticle delivery to E-selectin- or P-selectin-positive cells or tissues. In particular, this invention discloses a method for preparing quinic acid-modified nanoparticles for targeted drug delivery to cancerous cells or tissues via E-selectin- or P-selectin-mediated transcytosis. The invention described herein also pertains to pharmaceutical compositions and methods for treating cancers.

公开(公告)号：US10398651B2

公开(公告)日：2019-09-03

申请号：US15624303

申请日：2017-06-15

Applicant: Purdue Research Foundation

Inventor： Yoon Yeo ,  Joonyoung Park ,  Bo Sun

IPC: A61K9/16 ,  A61K31/337 ,  A61K9/00 ,  A61K47/10 ,  A61K9/51

Abstract: A carrier free nanoparticle formulation with good circulation stability is made for anticancer drug delivery. Nanocrystals crystallized in the medium containing Pluronic F-127 then coated with albumin (Cim-F-Alb) had the smallest size and the most native albumin, and showed most favorable cell interaction profiles and better stability than commercial albumin based Abraxane formulation, while maintaining comparable cytotoxicity to those of Abraxane and solvent-dissolved paclitaxel (PTX).

公开(公告)号：US20240180849A1

公开(公告)日：2024-06-06

申请号：US18285439

申请日：2022-04-12

Applicant: Purdue Research Foundation

Inventor： Yoon Yeo ,  Jianping Wang ,  Fanfei Meng

IPC: A61K9/70 ,  A61K45/06 ,  A61K47/59 ,  A61K49/00 ,  A61P35/00 ,  C12N15/113

CPC classification number: A61K9/70 ,  A61K45/06 ,  A61K47/59 ,  A61K49/0054 ,  A61P35/00 ,  C12N15/1138 ,  A61K2123/00 ,  C12N2310/141

Abstract: The present disclosure generally relates to a composition matter and a method for cancer treatment. In particular, a composition matter as an antitumor immunotherapy comprising a polyethyleneimine derivative as an immunoadjuvant, a chemotherapeutic drug, and optional components such as a microRNA, messenger RNA, plasmid DNA, siRNA, oligonucleotide, or a cyclic dinucleotide. A method for treating a subject with a cancer by administrating a therapeutic effective amount of a composition comprising a polyethyleneimine derivative and an antitumor agent to the subject in need of relief from said cancer is also within the scope of this disclosure.

公开(公告)号：US11865158B2

公开(公告)日：2024-01-09

申请号：US17636453

申请日：2020-08-21

Applicant: PURDUE RESEARCH FOUNDATION

Inventor： Yoon Yeo ,  Simseok Yuk

IPC: A61K38/17 ,  A61P37/00 ,  A61K9/51 ,  A61K31/7032 ,  A61K33/26 ,  A61K38/12 ,  A61K47/10 ,  A61K47/36

CPC classification number: A61K38/1709 ,  A61K9/5123 ,  A61K31/7032 ,  A61K33/26 ,  A61K38/12 ,  A61K47/10 ,  A61K47/36 ,  A61P37/00

Abstract: The present invention generally relates to a process of nanoparticle formulations and its composition matter for systemic treatment of sepsis. In particular, this invention discloses a method for preparing tannic acid-ferric nanoparticles, optionally incorporating a component of vitamin D3, coated with zwitterionic chitosan (ZWC) and polymyxin B (PMB). The invention described herein also pertains to pharmaceutical compositions and methods for the treatment of sepsis.

公开(公告)号：US10526605B2

公开(公告)日：2020-01-07

申请号：US16026609

申请日：2018-07-03

Applicant: Purdue Research Foundation

Inventor： Wanqing Liu ,  Yoon Yeo

IPC: C12N15/11 ,  C12N15/113 ,  A61K31/713 ,  A61K31/7088 ,  A61K47/58 ,  A61K47/54 ,  A61K47/59 ,  A61K47/69

Abstract: The invention provides siRNA compositions that specifically downregulates expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD).

公开(公告)号：US10036024B2

公开(公告)日：2018-07-31

申请号：US15614147

申请日：2017-06-05

Applicant: Purdue Research Foundation

Inventor： Wanqing Liu ,  Yoon Yeo

IPC: C12N15/11 ,  C12N15/113 ,  A61K31/713 ,  A61K31/7088 ,  A61K47/48

CPC classification number: C12N15/1137 ,  A61K31/7088 ,  A61K31/713 ,  A61K47/554 ,  A61K47/58 ,  A61K47/59 ,  A61K47/6923 ,  A61K47/6933 ,  C12N2310/14 ,  C12N2310/351 ,  C12N2320/32 ,  C12N2320/34 ,  C12Y301/01003

Abstract: The invention provides siRNA compositions that specifically downregulates expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD).

公开(公告)号：US20170360709A1

公开(公告)日：2017-12-21

申请号：US15624303

申请日：2017-06-15

Applicant: Purdue Research Foundation

Inventor： Yoon Yeo ,  Joonyoung Park ,  Bo Sun

IPC: A61K9/16 ,  A61K31/337

CPC classification number: A61K9/167 ,  A61K9/0019 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/1658 ,  A61K9/5161 ,  A61K9/5169 ,  A61K9/5192 ,  A61K31/337 ,  A61K47/10

Abstract: A carrier free nanoparticle formulation with good circulation stability is made for anticancer drug delivery. Nanocrystals crystalized in the medium containing Pluronic F-127 then coated with albumin (Cim-F-Alb) had the smallest size and the most native albumin, and showed most favorable cell interaction profiles and better stability than commercial albumin based Abraxane formulation, while maintaining comparable cytotoxicity to those of Abraxane and solvent-dissolved paclitaxel (PTX).

公开(公告)号：US20230414514A1

公开(公告)日：2023-12-28

申请号：US18134109

申请日：2023-04-13

Applicant: Purdue Research Foundation

Inventor： Luis Solorio ,  Anastasiia Vasiukhina ,  Yoon Yeo ,  Sheryhan F. Gad

IPC: A61K9/16 ,  A61K9/00

CPC classification number: A61K9/1647 ,  A61K9/0073

Abstract: A formulation to deter abuse of a drug by smoking comprising a physical barrier having properties to entrap the drug and thermal degradation products thereof. The physical barrier is in the form of an additive or a polymer network or a combination thereof.